Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
 BACK TO LIST

European Patient Summary

Patient
Name: Neary, , Meaghan,
DOB: 19-DEC-1960 (Age: 64)
Gender: female
ID: 1586-567257-8 (ECI)
Author
Dr. Ping, Hel
Patient summary Document
European Patient Summary
Report Date: 16-JUL-2025

Problem list

Condition Onset Date Status
Hyperlipidemia 25-Jun-2024 active
Chronic kidney disease stage 3 23-Apr-2019 active
Proteinuria due to type 2 diabetes mellitus 23-Apr-2019 active
Chronic kidney disease stage 2 27-Aug-2013 active
Microalbuminuria due to type 2 diabetes mellitus 27-Aug-2013 active
Disorder of kidney due to diabetes mellitus 18-Jul-2006 active
Chronic kidney disease stage 1 18-Jul-2006 active
Metabolic syndrome X 02-Jun-1998 active
Anemia 27-May-1997 active
Prediabetes 10-May-1994 active
Essential hypertension 16-Apr-1991 active

Medication list

Medication Since Form Dosage Reason
Simvastatin 10 mg oral tablet 2025-07-15 - 1 tablet (10 mg) by mouth once daily Hyperlipidemia
insulin isophane human 70 UNT/ML / insulin regular human 30 UNT/ML Injectable Suspension [Humulin] 2025-06-16 - 10 units subcutaneously twice daily before breakfast and dinner Prediabetes
Amlodipine (as amlodipine besylate) 2.5 mg oral tablet 2025-06-16 - 1 tablet (2.5 mg) by mouth once daily Essential hypertension (disorder)
Vitamin B12 5 MG/ML Injectable Solution 1997-06-02 - 5 mg (1 mL) intramuscularly once weekly -

Immunizations list

Vaccine Date
Influenza virus antigen only vaccine product 28-Apr-2025
Streptococcus pneumoniae Danish serotype 1 21-Oct-2024
Streptococcus pneumoniae Danish serotype 1 11-Dec-2023
SARS-CoV-2 mRNA vaccine 20-Dec-2021
Clostridium tetani toxoid antigen adsorbed only vaccine product 30-Sep-2019

Procedure History list

Procedure Date Reason
Depression screening 20-May-2025 -
Screening for domestic abuse 20-May-2025 -
Depression screening using Patient Health Questionnaire Two-Item score (procedure) 20-May-2025 -
Assessment of health and social care needs 19-May-2025 -
Assessment of anxiety 19-May-2025 -
Assessment using Morse Fall Scale 19-May-2025 -
Assessment using AUDIT-C (Alcohol Use Disorders Identification Test - Consumption) 18-Mar-2025 -
Assessment of substance use 18-Mar-2025 -
Medication reconciliation 17-Mar-2025 -
Screening for drug abuse 21-May-2024 -
Pre-discharge assessment 01-Dec-2023 -
Discharge from skilled nursing facility (procedure) 01-Dec-2023 -
Nursing care/supplementary surveillance 30-Nov-2023 -
Occupational therapy 29-Nov-2023 -
Professional / ancillary services care 22-Nov-2023 -
Physical therapy procedure 18-Nov-2023 -
Speech and language therapy regime 31-Oct-2023 -
Care regimes assessment 23-Oct-2023 -
History AND physical examination 02-Oct-2023 -
Initial patient assessment 02-Oct-2023 -
Development of individualized plan of care 02-Oct-2023 -
Depression screening using PHQ-9 (Patient Health Questionnaire 9) score 19-Jul-2022 -
Radiography of wrist 27-Dec-2015 -
Bone immobilization 27-Dec-2015 Fracture subluxation of wrist
Bone density scan 27-Dec-2015 Fracture subluxation of wrist

Allergies and Intolerances

Allergy/Intolerance Onset Date Status Type Reaction
? active ?

Care Plan

Active Planned Care / Goals Start Date Reason
Hyperlipidemia clinical management plan 16-Jul-2024 Hyperlipidemia
  • Reduce LDL cholesterol to target level
  • Reduce total cholesterol to target level
  • Reduce triglycerides to target level
  • Increase HDL cholesterol to target level
Diabetes self management plan 10-May-1994 Prediabetes
  • Achieve and maintain Hemoglobin A1c below 6.5% through diabetes self-management.
  • Achieve and maintain a healthy body weight as part of diabetes self-management.
  • Maintain blood pressure below 130/80 mmHg through lifestyle modifications.
  • Achieve and maintain LDL cholesterol below 2.6 mmol/L as part of diabetes self-management.
Lifestyle education regarding hypertension 16-Apr-1991 Essential hypertension (disorder)
  • Maintain blood pressure below 130/80 mmHg to reduce cardiovascular and renal risk.
  • Adopt dietary changes, increase physical activity, and reduce sodium intake to support blood pressure control.
Immunization Recommendation Due Date Reason
Vaccine product containing only Influenza virus antigen (medicinal product) 01-Oct-2025 Annual seasonal influenza vaccination

Vital Signs

Vital Signs 2025-06-16 2025-05-19
Body Height 169.5 cm 169.5 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported 1 {score} 2 {score}
Body Weight 80.6 kg 80.6 kg
Body mass index (BMI) [Ratio] 28.1 kg/m2 28.1 kg/m2
Diastolic Blood Pressure 91 mm[Hg] 89 mm[Hg]
Systolic Blood Pressure 111 mm[Hg] 110 mm[Hg]
Heart rate 79 /min 65 /min
Respiratory rate 14 /min 14 /min

Relevant diagnostic tests/laboratory data

Recent Lab Observations 16-JUL-2025 Reference Range Unit
Glucose [Mass/volume] in Blood 75.1 70 - 100 mg/dL
Urea nitrogen [Mass/volume] in Blood 18.0 7 - 43 mg/dL
Creatinine [Mass/volume] in Blood 2.9 H 0.6 - 1.1 mg/dL
Calcium [Mass/volume] in Blood 9.8 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 137.5 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.6 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 105.3 98 - 108 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 25.3 22 - 29 mmol/L
Protein [Mass/volume] in Serum or Plasma 6.7 6 - 8.3 g/dL
Albumin [Mass/volume] in Serum or Plasma 5.2 3.5 - 5.5 g/dL
Globulin [Mass/volume] in Serum by calculation 3.2 2 - 3.5 g/L
Bilirubin.total [Mass/volume] in Serum or Plasma 0.1 L 0.3 - 1.2 mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 80.2 44 - 130 U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 53.4 0 - 55 U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 10.6 10 - 40 U/L
Cholesterol [Mass/volume] in Serum or Plasma 199.1 125 - 239 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 113.4 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 142.4 H 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 74.2 50 - 100 mg/dL

Device Use

Device Date (since)
Blood glucose meter (physical object) 09-May-1994